Your browser doesn't support javascript.
loading
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Roviello, Giandomenico; Gambale, Elisabetta; Giorgione, Roberta; Santini, Daniele; Stellato, Marco; Fornarini, Giuseppe; Rebuzzi, Sara Elena; Basso, Umberto; Bimbatti, Davide; Doni, Laura; Nesi, Gabriella; Bersanelli, Melissa; Buti, Sebastiano; De Giorgi, Ugo; Galli, Luca; Sbrana, Andrea; Conca, Raffaele; Carella, Claudia; Naglieri, Emanuele; Pignata, Sandro; Procopio, Giuseppe; Antonuzzo, Lorenzo.
Afiliação
  • Roviello G; Department of Health Sciences, University of Florence, Florence, Italy.
  • Gambale E; Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Giorgione R; Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Santini D; Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
  • Stellato M; Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
  • Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino di Genova, Genoa, Italy.
  • Rebuzzi SE; Medical Oncology Unit, San Paolo General Hospital, Savona, Italy.
  • Basso U; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genoa, Italy.
  • Bimbatti D; MedicalOncology Unit 1, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
  • Doni L; MedicalOncology Unit 1, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
  • Nesi G; Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Bersanelli M; Department of Health Sciences, University of Florence, Florence, Italy.
  • Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • De Giorgi U; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Galli L; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Italy.
  • Sbrana A; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Conca R; Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
  • Carella C; Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
  • Naglieri E; Istituto Oncologico Giovanni Paolo II, Bari, Italy.
  • Pignata S; Istituto Oncologico Giovanni Paolo II, Bari, Italy.
  • Procopio G; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
  • Antonuzzo L; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Cancer Med ; 11(16): 3084-3092, 2022 08.
Article em En | MEDLINE | ID: mdl-35312175
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Antineoplásicos Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Antineoplásicos Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article